X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Recent administration actions undermine patient assistance programs

By Nicole Longo  |    September 16, 2020
While all eyes and ears are focused on COVID-19 and beating this pandemic, the administration has pursued harmful policy changes that we can’t let slip under the radar. In two back-to-back...   Read More

Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually

By Gabby Migliara  |    August 19, 2020
A recent analysis by IQVIA shows that chronically ill patients who used manufacturer cost-sharing assistance in 2019 saved hundreds to thousands of dollars on their out-of-pocket costs. IQVIA...   Read More

PhRMA submits comments to CMS on Medicaid proposed rule

By Nicole Longo  |    July 21, 2020
In response to the Centers for Medicare and Medicaid Services’ (CMS) proposed rule regarding changes to Medicaid, PhRMA provided feedback on how the changes included would have widespread impacts...   Read More

ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements

By Katie Koziara  |    April 20, 2020
Value-based programs between biopharmaceutical companies and pharmacy benefit manager Express Scripts saved $4.3 billion on medicines last year. Patients in these plans with innovative contracting...   Read More

Addressing barriers that inhibit value-based contracts

By Katie Koziara  |    February 21, 2020
With 56 new medicines approved by the U.S. Food and Drug Administration (FDA) in 2019 and over 8,000 medicines in development around the globe, innovative medicines are transforming the way we...   Read More

New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

By Katie Koziara  |    November 4, 2019
A new analysis from Xcenda applied the Institute for Clinical and Economic Review’s (ICER) value assessments to state Medicaid programs in California, Massachusetts, Maryland, Nevada and New York....   Read More

New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid

By Katie Koziara  |    March 20, 2019
A new analysis from Xcenda found that if Medicaid were to use one-size-fits-all value assessments like the Institute for Clinical and Economic Review’s (ICER) framework as the basis for accessing...   Read More

ICYMI – Two PBM reports show dramatic slowdown in medicine spending growth

By Holly Campbell  |    March 2, 2018
Newly released pharmacy benefit manager (PBM) data show medicine spending is growing at the slowest rate in years. After accounting for discounts and rebates negotiated with biopharmaceutical...   Read More

New report shows better diabetes management saves money and improves patient outcomes

By Carolyn Ha  |    November 21, 2017
A recent IHS Markit report, “The Clinical and Economic Benefits of Better Treatment of Adult Medicaid Beneficiaries with Diabetes,” simulated savings in the Medicaid program as a result of better...   Read More

Local Impact: Hepatitis C and Medicaid spending

By Priscilla VanderVeer  |    December 22, 2015
There has been a lot of discussion about the cost of new hepatitis C treatments to state Medicaid programs. What has not been addressed, however, is how those costs stack up against older, less...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates